Production (Stage)
Palvella Therapeutics, Inc.
PVLA
$25.40
$1.918.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.91M | -13.26M | 11.23M | 15.17M | 15.66M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.59M | 5.22M | -18.64M | -19.24M | -23.74M |
| Change in Net Operating Assets | -2.59M | -1.19M | 1.14M | -2.58M | -2.65M |
| Cash from Operations | -14.90M | -9.24M | -6.27M | -6.65M | -10.73M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 8.43M | 8.43M | 7.43M | 5.00M | 5.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 60.07M | 60.00M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 7.49M | 8.76M | -21.00K | -- | -- |
| Cash from Financing | 76.00M | 77.20M | 7.41M | 5.00M | 5.00M |
| Foreign Exchange rate Adjustments | -3.00K | 3.00K | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 61.09M | 67.96M | 1.14M | -1.65M | -5.73M |